Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Everolimus 9Temozolomide 7Sunitinib 7Specimen Handling 4Octreotide 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4lutetium Lu 177 dotatate 3Leucovorin 3sargramostim 2montanide ISA 51 2incomplete Freund's adjuvant 2cabozantinib 2Thalidomide 2Streptozocin 2Sorafenib 2Oxaliplatin 2Irinotecan 2Injections 2Endoscopic Ultrasound-Guided Fine Needle Aspiration 2Doxorubicin 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1sapanisertib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × recombinant interferon alpha 2b-like protein × Clear all
NCT02455596 2016-01-05

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase 2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡